These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18722865)

  • 61. Mesothelioma: closer to the target?
    Pass HI
    Lancet Oncol; 2013 May; 14(6):448-9. PubMed ID: 23583605
    [No Abstract]   [Full Text] [Related]  

  • 62. Combining chemotherapy with virotherapy: a novel treatment strategy for malignant pleural mesothelioma.
    Curiel DT; Zhu ZB
    Cancer Biol Ther; 2006 Feb; 5(2):236-7. PubMed ID: 16481733
    [No Abstract]   [Full Text] [Related]  

  • 63. [Thrombotic microangiopathy associated with cancer is an oncologic emergency: a case report].
    Blot E; Marie I; Delastre O; Cailleux N; Pouillart P; Lévesque H; Courtois H
    Rev Med Interne; 1999 May; 20(5):448-9. PubMed ID: 10365422
    [No Abstract]   [Full Text] [Related]  

  • 64. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
    ; Manegold C
    Ann Oncol; 2007 Apr; 18 Suppl 2():ii34-5. PubMed ID: 17491037
    [No Abstract]   [Full Text] [Related]  

  • 65. Treatment of diffuse pleural malignant mesothelioma by cis dichloro diammine platinum (C.D.D.P.) in nine patients.
    Dabouis G; Le Mevel B; Corroller J
    Cancer Chemother Pharmacol; 1981; 5(3):209-10. PubMed ID: 7197593
    [No Abstract]   [Full Text] [Related]  

  • 66. Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma?
    Vogelzang NJ
    J Clin Oncol; 1999 Aug; 17(8):2626-7. PubMed ID: 10561332
    [No Abstract]   [Full Text] [Related]  

  • 67. Better treatments needed for breast cancer brain metastases.
    Lin NU
    Lancet Oncol; 2015 Dec; 16(16):1583-4. PubMed ID: 26596673
    [No Abstract]   [Full Text] [Related]  

  • 68. ECCO 11 The European Cancer Conference: Lisbon, Portugal, October 21-25, 2001.
    Johnson L; Fisher M
    Clin Prostate Cancer; 2002 Jun; 1(1):6-11. PubMed ID: 15046706
    [No Abstract]   [Full Text] [Related]  

  • 69. Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Vinorelbine: an update and review of activity.
    Macbeth F
    Clin Oncol (R Coll Radiol); 1997; 9(3):197. PubMed ID: 9269558
    [No Abstract]   [Full Text] [Related]  

  • 70. Vinorelbine in pregnancy.
    Cuvier C; Espie M; Extra JM; Marty M
    Eur J Cancer; 1997 Jan; 33(1):168-9. PubMed ID: 9071921
    [No Abstract]   [Full Text] [Related]  

  • 71. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.
    Karrison TG; Vogelzang NJ
    Cancer; 1999 Aug; 86(3):546-7. PubMed ID: 10430267
    [No Abstract]   [Full Text] [Related]  

  • 72. Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.
    Fennell DA; Dulloo S
    J Thorac Oncol; 2022 Jan; 17(1):34-37. PubMed ID: 34930610
    [No Abstract]   [Full Text] [Related]  

  • 73. R.N.A. therapy for pleural mesothelioma.
    Esposito S
    Lancet; 1969 Nov; 2(7631):1203-4. PubMed ID: 4187239
    [No Abstract]   [Full Text] [Related]  

  • 74. Malignant Mesothelioma and Delivery of Polyphenols.
    Bishop KS; Braakhuis AJ; Ferguson LR
    Nutrients; 2016 Jun; 8(6):. PubMed ID: 27271656
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Phase II trials of malignant mesothelioma: a commentary and update.
    Krarup-Hansen A
    Lung Cancer; 1994 Sep; 11(3-4):305-8. PubMed ID: 7812708
    [No Abstract]   [Full Text] [Related]  

  • 76. Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma.
    Sobhani N; Roviello G; Corona SP; Ianza A; Zanconati F; Generali D
    Lung Cancer; 2017 Dec; 114():103-105. PubMed ID: 28757047
    [No Abstract]   [Full Text] [Related]  

  • 77. Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study.
    Cowan JD; Green S; Lucas J; Weick JK; Balcerzak SP; Rivkin SE; Coltman CA; Baker LH
    Invest New Drugs; 1988 Sep; 6(3):247-8. PubMed ID: 3192391
    [No Abstract]   [Full Text] [Related]  

  • 78. Commentary: Regional oncolytics for pleural malignancies.
    Amador A; Byun AJ; Adusumilli PS
    J Thorac Cardiovasc Surg; 2022 Apr; 163(4):e330-e331. PubMed ID: 33454094
    [No Abstract]   [Full Text] [Related]  

  • 79. MVP and vinorelbine for malignant pleural mesothelioma.
    Mordant P; Loriot Y; Soria JC; Deutsch E
    Lancet; 2008 Aug; 372(9639):629; author reply 629-30. PubMed ID: 18722865
    [No Abstract]   [Full Text] [Related]  

  • 80. Malignant mesothelioma--the UK experience.
    O'Brien ME
    Lung Cancer; 2004 Aug; 45 Suppl 1():S133-5. PubMed ID: 15261447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.